Risk Factors for Chronic Cough in Young Children: A Cohort Study

Data on the predictors of chronic cough development in young children are scarce. Our primary objective was to examine the factors associated with young children developing a chronic cough, with a focus on childcare attendance

Effect of erdosteine on the rate and duration of COPD exacerbations: the REST…

Oxidative stress contributes to chronic obstructive pulmonary disease (COPD) exacerbations and antioxidants can decrease exacerbation rates, although we lack data about the effect of such drugs on exacerbation duration. The RESTORE (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine in COPD) study was a prospective randomised, double-blind, placebo-controlled study, enrollin…

Erdosteine : evaluation of murorheological and immunosecretory parameters in …

Edition

-

ISBN/ISSN

-

Collation

-

Series Title

-

Call Number

-

Effectiveness of Erdosteine in Elderly Patients with Bronchiectasis and Hyper…

Mucus plugging and hypersecretion have been associated with an increased relative risk of death in patients with bronchiectasis who may or may not have chronic obstructive pulmonary disease (COPD), which is of prognostic relevance in the elderly. However, chest physiotherapy and/or the use of mucoactive agents is considered to be an effective therapeutic model in treating patients with COPD and…

Activity of erdosteine on mucociliary transport in patients affected by chron…

Edition

-

ISBN/ISSN

-

Collation

-

Series Title

-

Call Number

-

The therapeutic efficacy of erdosteine in the treatment of chronic obstructiv…

Erdosteine, a drug approved for the treatment of acute and chronic pulmonary diseases, has been shownrnto be an effective treatment for chronic bronchitis or COPD (CB/COPD) in several studies, althoughrnmarked differences in the perception of its usefulness still remain.

Erdosteine in children and adults with bronchiectasis (BETTER trial): study p…

Bronchiectasis is a worldwide chronic lung disorder where exacerbations are common. It affects people of all ages, but especially Indigenous populations in high-income nations. Despite being a major contributor to chronic lung disease, there are no licensed therapies for bronchiectasis and there remain relatively few randomised controlled trials (RCTs) conducted in children and adults. Our RCT…

Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent